Activating BRAF mutations are thought to drive melanoma tumorigenesis and metastasis by constitutively activating MEK and ERK. Small molecule inhibitors (SMIs) of BRAF or MEK have shown promise as melanoma therapeutics. However, the development of resistance to these inhibitors in both the short-and long-term is common; warranting investigation into how these SMIs influence ERK signaling dynamics. Quantitative single cell imaging of ERK activity in living cells reveals both intra-and inter-cell heterogeneity in this activity in isogenic melanoma populations harboring a BRAFV600E mutation. This heterogeneity is largely due to a cell-cycle dependent bifurcation of ERK activity.
Introduction
Extracellular signal-regulated kinase (ERK) activity regulates a diverse array of distinct, and sometimes even opposing, behaviors (1) . ERK activity is frequently upregulated in cancers following activating mutations in RAS (NRAS and KRAS) and BRAF genes (2, 3) , and/or mutations in negative regulators that inhibit the activity of ERK such as NF1, c-KIT or RASA2 (4, 5, 6, 7) . Understanding how ERK activity regulates cell fate in cancer cells is key to developing and deploying therapies that suppress ERK activation. Such insight is particularly relevant to melanomas, which are almost all dependent on ERK activation for their progression, but where inhibitors of the ERK pathway appear to have limited effectiveness clinically (8, 9, 10, 11, 12, 13, 14, 15) .
In normal cells, there is cell-to-cell variability in the dynamics of ERK activation in response to the same stimulus (16) . These variations can be a consequence of noise in the activity of upstream activators such as MEK (17) , or the duration of the activating signal (i.e. pulsatile versus transient) (18) . Additional factors such as spatial position within a multicellular environment (16) , differences in protein abundance (19) , and/or cell shape (20, 21) can also underpin cell-to-cell variability in ERK activity. Such cell-to-cell variation in ERK activity likely contributes to different outcomes during cell fate decisions (22, 23) .
While in some populations ERK activation appears to be an "all-or-none" event (24, 25, 26) , ERK activity has also been demonstrated to oscillate in both frequency-independent (27) , and frequency-modulated (28) fashions; as well as having dampened oscillatory activity (29, 30) . Thus, some normal cells also display within-cell variability in ERK dynamics. Most likely, the dynamics of ERK activation are influenced by similar factors to those which have been observed to affect cell-to-cell variation, as well as cell-and cue-specific signaling network topologies that both activate ERK, and modulate its activity through positive and negative feedback (32, 33, 24, 34, 36, 37) .
Most of our understanding of ERK activation dynamics comes from normal cell models, where ERK activity is tightly modulated, and the full dynamic range of ERK activity in response to a cue can be explored. How activating mutations in upstream kinases such as BRAF affect cell-to-cell variation in ERK activity, and response in cancer cells is markedly less clear; as little has been done to explore how ERK dynamics in single cells with activating mutations in upstream activators/inhibitors. Furthermore, little is understood as to how ERK activity responds in single cells with activating mutations in BRAF or MEK during chemical manipulation of upstream signaling. In the absence of such studies, we have little insight into how therapies that are given to cancer patients affect ERK signaling dynamics in individual cells -which could dictate the timing and dose of therapy (39), and be important in the emergence of therapeutically resistant sub-populations (18) .
Here we aimed to assess the impact of a BRAF V600E mutational background on the dynamics of ERK signaling and how those dynamics are altered in response to clinically relevant inhibitors targeting the ERK pathway.
Results

ERKTR ratio illustrates cellular heterogeneity in ERK activity
To the Tyr202/Thr204 MEK phosphorylation site. BRAF-MEK-ERK activity is determined by quantifying the log10 of cytoplasmic:nuclear ratio of ERKTR intensity, or single phospho-ERK intensity, rescaled to a 0-10 range ( Figure 1A ; Methods). Phospho-ERK levels and the ratio of cytoplasmic:nuclear ERKTR (hereafter referred to as 'ERKTR ratio') were positively correlated across conditions (Supplementary Figure 2) . The decrease in both phospho-ERK levels and ERKTR ratio following BRAF or MEK inhibition, demonstrates that the ERKTR ratio faithfully reports BRAF-MEK-ERK activity in single melanoma cells.
Notably however, there is considerable heterogeneity in both phospho-ERK and ERKTR ratios in melanoma cells after treatment with BRAF or MEK inhibitors.
To characterize the heterogeneity of BRAF-MEK-ERK pathway activity, we plotted histograms of ERKTR ratios in single cells from untreated populations, and those treated with small molecule inhibitors (SMIs) of BRAF-MEK-ERK signaling. As negative controls we quantified ERK activity in A375p ERKTR cells treated with Wee1 (MK-1775) and mTOR (Temsirolimus) inhibitors ( Figure 1D, Supplementary Figure 3) . In unperturbed cells (black curve, Figure 1D ), the mean ERKTR ratio is 5.86, indicating that most cells have cytoplasmic ERKTR -and active BRAF-MEK-ERK signaling. However, the distribution of ERKTR ratios in normal cell populations exhibited a considerable negative skew (skewness=-0.629); thus, in normal A375p ERKTR there is also significant sub-population of cells with low BRAF-MEK-ERK activity ( Figure 1D To determine if melanoma cells exhibit similar heterogeneity in BRAF-MEK-ERK activity in vivo, we generated tumors of A375p ERKTR cells in two immune-compromised mice, and imaged each tumor in live mice using two-photon confocal microscopy (Methods). We observed considerable heterogeneity in ERKTR ratios in vivo, including regional variation with "pockets" of cells where BRAF-MEK-ERK activity was decreased ( Figure 1E ). There was also significant variation in ERKTR ratios between the two tumors ( Figure 1F ). When we compiled data from both tumors, we observed that a significant population of cells (40.2%) had inactive BRAF-MEK-ERK pathway activity ( Figure 1G ). Thus, the existence of an activating BRAF V600E mutation in melanoma cells is insufficient to maintain constitutively high levels of BRAF-MEK-ERK activity in vivo.
ERK activity bifurcates after mitosis
To determine the basis for population-level heterogeneity in BRAF-MEK-ERK activity, we quantified ERKTR ratios in A375p ERKTR cells over time. ERK activity has been observed to exhibit large fluctuations in other cell types during the cell cycle (28, 44, 45, 46) , therefore, we engineered A375p ERKTR cells to also express a fluorescently tagged version of Proliferating Cell Nuclear Antigen (PCNA) (Figure 2A ) -which allowed to simultaneously quantify ERKTR ratios at different cell cycle phases. To demark S-phase we used automated image analysis methods (49) to identify a characteristic pattern of PCNA intensity increase, coinciding with a sharp peak in PCNA foci levels (47, Methods). From the timing of S-phase and mitosis, G1 and G2 phases can subsequently be inferred. After image analysis, we generated "tracks" of PCNA and ERKTR features over time, which can be aligned to different cell cycle transitions in silico.
Over multiple cell cycles, there was considerable intra-cell variation in ERKTR ratios.
Specifically, in ~23% of cells, ERKTR ratios in daughter cells (D) decreased by as much as 5-fold compared to their mother cells (M) upon mitotic exit ( Figure 2B ). The ERKTR ratios in a representative cell whose ERKTR ratio falls upon G1 arrest is shown in Figure   2C , and a representative cell maintaining high ERKTR ratio throughout the cell cycle is 8 shown in Figure 2D . We did not observe large fluctuations in ERKTR ratios outside the transition between mitosis and G1 in A375p cells, but observed oscillatory ERK dynamics in hTERT-RPE epithelial cells (Supplementary Figure 4A ,B.). We also ruled out the existence of high frequency fluctuations in ERKTR ratios by imaging live cells at 1 min intervals (Supplementary Figure 4C) . Thus, A375p melanoma cells exhibited considerable intra-cell variability in BRAF-MEK-ERK pathway activity, which can at least in part explain cell-to-cell differences observed at the population level. Figure 3) . Each row represents a single cell track with a color scale normalized to the ERK ratio across the whole data set (Methods).
While the addition of BRAF and both MEK inhibitors at sub-lethal concentrations (80 nM) (Supplementary Figure 5) , caused an eventual decrease in ERKTR ratios, the decrease occurred with two different types of kinetics. If BRAF or MEK is inhibited more than 13 hours prior to mitosis, the ERKTR ratio also decreased immediately. Given that the average length of S-phase in DMSO-treated A375p ERKTR cells was 6.5 hours (n=20), and the average G2 length was 4.3 hours (n=13), 13 hours prior to mitosis corresponds to a point in G1. However, if BRAF or MEK activity is inhibited less than 13 hours before mitosis, after G1, the ERKTR ratio remained high, or mildly decreased, until mitosis where it then dropped to a nadir ( Figure 3 ). Inhibition of Wee1 or mTOR has no effect on ERKTR ratios compared to DMSO treated cells. Taken 
Melanoma cells enter a quiescent-like state despite BRAF mutation
We hypothesized that the inactivation of ERK in G1 drives cells into an extended G1
arrest; which we defined as a cell not entering S-phase for 600 minutes or more (47). 
ERK activity is less sensitive to BRAF/MEK inhibition in S or G2 versus G1.
To precisely determine how cell cycle stage affected the ability of BRAF or MEK inhibitors to decrease ERK activity, we imaged A375p ERKTR/PCNA cells for 13.5 hours before adding either BRAF inhibitor Dabrafenib of MEK inhibitor Binimetinib. Consistent with our observations from cells that were treated with SMIs prior to imaging (Figure 3 ), we observed a large decrease in ERKTR ratio immediately in cells that were in early G1 when both drugs were, with a few notable exceptions added ( Figure 4A , B). In cells that were in G1 upon inhibitor addition, but entered S-phase shortly afterwards (late G1 cells), ERKTR ratios did not fall immediately, but instead remained high until the subsequent G1. Cells that were in S-phase or G2 at the time the inhibitors were added, showed a small decrease in ERKTR ratios, but the ratios remained relatively high levels until the next M/G1, whereupon the ratios dropped to their nadir ( Figure 4B ,C). The proportional decrease in ERKTR following SMI addition in S-phase or G2 vs the decrease following mitosis was 30% to 60%. To confirm that ERKTR ratios were less sensitive to BRAF or MEK inhibition in G2 and S phases versus G1 phase, we stained fixed A375p
ERKTR/PCNA cells for CyclinA2, which is only expressed in S-phase and G2 and classified cells as being in different cycle phases using image analysis ( Figure 4D , Methods). G1 cells showed a significant decrease in ERKTR ratio (p>0.001) after a 2 hour treatment with BRAF or MEK inhibitors while G2 and S-phase cells still have a significant (p>0.001), but much smaller, decrease in ERKTR ratios. Thus, consistent with our previous observations where SMI were added to asynchronous cultures prior to imaging, inhibition of BRAF or MEK suppresses a fraction of the ERK activity in S/G2, but the maximal effects of this inhibition occurs only following mitosis.
BRAF-MEK-ERK activity is dependent on cell cycle stage in in multiple BRAF mutant melanoma lines
Our observations suggest the of a positive feedback loop in A375p cells that is engaged during a point in G1 that can maintain ERK activity even following inhibition of BRAF or MEK. Such inhibition may also repress the actions of a negative feedback loops on ERK that are engaged following G1-S progression. A quiescent-like state must also negatively regulate BRAF-MEK-ERK activity that is otherwise activated by the BRAFV600E mutation. Figure 7C) . Strikingly, the effect of short-term combined CDK4/6 and BRAF/MEK inhibition was even observable on the whole population level, and not just in p-RB high/low populations ( Figure 7D ). Taken together these data suggest that Palbociclib sensitizes ERK activity to BRAF or MEK inhibition by preventing passage through the RP and the transition from a BRAF/MEK dependent to independent state.
In normal cells, mitogenic signaling converges on CDK2 activity, which together with the extent of DNA damage determines the outcome of the proliferation-quiescence decision (22, 23, 47, 58, 59) . We thus sought to determine the role of BRAF-MEK-ERK signaling in the regulation of CDK2 activity following BRAF or MEK inhibition; by monitoring CDK2 activity using a reporter we have developed (57) . Notably, short ( Figure 7b) . This suggests that ERK activity is responsive to CDK2 activity, and when CDK2 activity falls below a threshold, ERK activity also drops. We propose that entry into a quiescent-like state following decreases in ERK activity suppresses the ability of BRAFV600E to activate ERK, establishing a cell-cycle dependent negative-feedback loop
Discussion
By quantifying ERK activation dynamics using a reporter in living single cells, we have
shown that, despite the presence of an activating BRAFV600E mutation, melanoma populations exhibit considerable inter-and intra-cell variability in ERK activity, both in normal culture conditions and in vivo. This observation starkly contrasts with those made largely through bulk analysis methods such as Western blotting which have implied ERK is constitutively active in BRAFV600E cells (3, 62, 63, 64, 65, 65 We propose that in melanoma cells feedback mechanisms which promote and/or antagonize BRAF-MEK-ERK activity are controlled in cell-cycle dependent fashions. As in normal cells, the proliferation-quiescence decision in BRAFV600E melanoma cells is still dependent on the mitogenic/pro-proliferative cues via MEK-ERK (22, 23, 58, 59) . Whilst the presences of the BRAFV600E mutation largely circumvents the need for exogenous mitogen in melanoma cells, it is insufficient to override the actions of CDK inhibitors (CKIs) such as p21CIP1/WAF1 that can be upregulated following events such an endogenous DNA damage (47, 58, 59). Upregulation of CKIs, and/or down-regulation of CDK activity engages mechanisms that then down-regulate ERK activity ( Figure 9 ). This represents a form of negative feedback control on ERK activity by the cell cycle. That BRAFV600E cells bifurcation into proliferative and quiescent-like states suggests that the ability to enter a quiescent state is beneficial on either a single cell level (i.e. to repair damaged DNA), and/or the population level as it introduces phenotypic heterogeneity into the population which may represent a bet-hedging mechanism against unexpected future stress.
Wild-type BRAF is activated by both recruitment to the membrane by NRAS, as well as by
Receptor Tyrosine Kinase (RTK) mediated phosphorylation of residues in the kinase domain (67, 68, 69) . Although the V600E mutation can drive full activation of BRAF in melanoma cells that is both independent of RTKs and NRAS (70, 77) ; some BRAFV600E melanoma cell lines appear to remain dependent on NRAS for proliferation (3) Furthermore, mechanisms independent of BRAF-MEK kinase activity must be capable of maintaining ERK activity in S-G2 cells in the presence of BRAF/MEK inhibitors. Our data suggests that these mechanisms are likely to be dependent on increased CDK4/6 and/or CDK2 activity ("CDK activity" in Figure 9 ). Potentially KSR could act as a scaffold that promotes ERK kinase activity in the absence of MEK, or other ERK kinases could be (Figure 9. ). But the ability of S and G2 cells to sustain ERK following passage of the RP in a manner independent of BRAF or MEK could potentially represent a means by which tumor cells could survive exposure to BRAF and/or MEK inhibitors. Moreover, our data suggests that therapeutic combinations that stall cells in mitosis, such as spindle poisons or in G2, such as Flavopiridol (a broad range CDK inhibitor) may not be able to inhibit ERK successfully. Although we do not propose that simply being in late G1, S, or M is sufficient for cells to survive BRAF or MEK inhibition, we do speculate that differences in cell cycle progression may represent an opportunity for other adaptive or long-term resistant mechanisms to be engaged (8, 80, 81, 82, 83, 84) .
Our data also provide rationale for using CDK4/6 inhibitors in combination with BRAF or MEK inhibitors, as the number of cells driven into an ERK low quiescent-like by Dabrafenib or Binimetinib in combination with Palbociclib was greater than following treatment by any
Methods and Materials
Generation of fluorescently labeled reporter cell lines
ERK activity was measured using pMSCV-puro-ERKTR-mCherry (donated by Prof.
J.G.Albeck). This reporter was originally published in Regot et al, 2014 (40). The average intensities of fluorescence were measured from the nucleus and ring region, and the log10 of the ratio (ring region/nuclear region calculated and referred to as ERKTR ratio. This value was rescaled between 0-10 for clarity in each experiment.
CDK2 activity was measured using pIRES-GFP-PSLD-Puro (CDK2L-GFP) donated by Dr.
A.R. Barr. This reporter was originally published in Barr et al, 2016 (57) . The average intensities of fluorescence were measured from the nucleus and ring region, and the log10 of the ratio (ring region/nuclear region calculated and referred to as CDK2L ratio).
Cell cycle stage was determined using pIRES-GFP-PCNA-Puro-2b. This plasmid was donated by Dr Alexis Barr, and was originally published in Leonhardt et al 2000 (99) .
Monoclonal cell lines were created by transfecting A375p (BRAF V600E) melanoma cells with plasmids using a standard lipofectamine 2000 method. Antibiotic selection was applied for a minimum of 7 days and single cells selected onto a 96well plate by FACS.
Cell lines were maintained in DMEM with 10%FBS and 1% Pen/Strep and minimal level of selection agent.
Live Cell Imaging
Live cell imaging was performed using a High-content Opera Spinning disk confocal microscope (PerkinElmer) with x20 air objective. All live cell imaging was carried out in an environmental chamber at 37°C, 5% CO 2 and 80% humidity.
Cells were plated 24hours prior to imaging onto 384 well Perkin Elmer Cell Carrier plates in 25ul DMEM (with 10% serum (FBS) and 1% Pen/Strep). SMIs or DMSO were added on top in 25ul at double concentration and plates were centrifuged for 1minute at 1000rpm.
Imaging began at 15minutes after drug addition or as specifically stated.
Feature extraction
After imaging the, files were combined and live cell movies were processed using customized MATLAB scripts for cell tracking and feature extraction as (47) using NucliTrack (49). ERKTR ratio was used to measure ERK activity. The mean intensity of ERKTR fluorescence in a ring region was measured by marking a mask overlaid onto segmented nuclei and being defined as an area of 7pixels wide surrounding the nucleus.
The nuclear intensity of EKRTR was measured by taking the average intensity of ERKTR fluorescence in the segmented nucleus. The ERKTR ratio was calculated by taking dividing the ring region intensity by the nuclear intensity and the Log10 of this was used as the output of ERKTR ratio due to the non-linear scaling of ratiometric values. CDK2 activity was measured in the same way and referred to as CDK2L ratio. Cell cycle stage was demarked using mean intensity of PCNA, which increases in S-phase, and unidirectional standard deviation of PCNA to measure only bright PCNA foci, which appear in S-phase (48). Mitosis was annotated to the track semi-automatically.
High Content Immunofluorescence
Cell were seeded onto Perkin Elmer Cell Carrier 384 well plates and allowed to grow for 24hours under normal cell culture conditions. SMIs were added for the time specified (24hours or 2 hours) and cells were fixed at 37°C for 10minutes with 4% formaldehyde.
Cells were permeablized for 15mins with 0.01% Triton1000 in PBS at RT, and blocked with 2%BSA in PBS for 2hours. Primary antibodies were diluted 1/1000 in blocking buffer and incubated at 4°C overnight. Alexa Fluorophore-conjugated secondary antibodies (Invitrogen) diluted 1:1000 in blocking buffer were incubated on cells for 1 hour at RT.
Hoechst was diluted 1:1000 in PBS and incubated on cells for 10mins at RT. Primary antibodies used are as follow: phosphoThr202/Tyr204 ERK 42/44 (Cell Signaling), phosphoS808/811 RB (Cell Signaling). Fixed imaged were processed using Columbus (PerkinElmer) for cell segmentation and feature extraction.
Cell Cycle stage determination in fixed cells
Cell populations were first grouped by CyclinA2 intensity to separate G1 cells from S or G2 cells. We then applied a linear classifier on nuclear PCNA texture features to determine cells with characteristic S-phase PCNA foci or G2 cells with smooth PCNA texture. The linear classifier had a goodness of 3.16 and an offset of -13.86. The features measured for the linear classifier were:
• Nucleus Ratio Width to Length
• Nucleus Length
• Nucleus Width
• Nucleus Roundness
• Nucleus Area
• Nucleus PCNA Gabor Max 2 px w2
• Nucleus PCNA Gabor Min 2 px w2
• Nucleus PCNA Haralick Homogeneity 1 px 
